.png?width=816&height=426&name=Copy%20of%20Copy%20of%20Copy%20of%20Copy%20of%20Copy%20of%20Copy%20of%20Press%20(1).png)
Canopy, the leader in Enterprise AI for oncology, today announced a partnership with the University of South Alabama (USA) Health Mitchell Cancer Institute, an academic research and treatment facility in Mobile, Alabama, to transform patient support between visits.
USA Health selected Canopy’s AI-native platform to replace legacy systems, aiming to extend the benefits of Remote Therapeutic Monitoring (RTM) across increasingly complex therapies while reducing operational burden for staff.
"We’re always looking for better ways to support our patients, especially when they’re away from the clinic. Canopy’s technology helps our staff stay connected with patients, identify issues earlier, and automate routine tasks so they can spend more time on what matters most.”
—Theresa McLaughlin, Administrative Director for Mitchell Cancer Institute
Canopy helps cancer centers manage the growing complexity of care by providing a unified AI platform across patient services: triage, call center, front office, referrals, and pharmacy. By embedding AI and automation into existing workflows, Canopy enables faster issue resolution, reduces manual work, and helps practices capture sustainable reimbursement.
"We’re proud to partner with USA Health as they bring innovative therapies to patients. Our goal is to help deliver on the promise of those therapies while empowering their team with Enterprise AI tools purpose-built for oncology."
—Lavi Kwiatkowsky, Founder and CEO of Canopy
Studies demonstrating the potential impact of Canopy’s platform on oncology patient experience in real-world settings have demonstrated:
- 22% reduction in ER visits and hospitalizations per 100 patient months1
- 22% - 45% improvement in treatment persistence at three months2
- 88% sustained patient engagement at six months3
- 52% reduction in infection-related hospitalizations in patients with hematologic malignancies, resulting in $977,695 in estimated annual savings per 1,000 patients4
- Improved early detection of toxicities with bispecific antibody therapies5
- Potential to improve adherence and manage toxicities associated with oral anticancer medication6
USA Health Mitchell Cancer Institute is the first academic cancer center to join Canopy’s rapidly growing network of 500+ unique sites of care.
About Canopy
Canopy is the leader in Enterprise AI for Oncology, providing practices with a unified platform for all the care that happens between visits and across patient services. Supporting a growing network of more than 2,000 oncology providers across 500+ sites of care nationwide, Canopy enables practices to identify and prioritize patients who need help, resolve their issues using AI-native tools, and generate new reimbursement streams. For more information, visit www.canopycare.us.
About the University of South Alabama Health Mitchell Cancer Institute
As part of the University of South Alabama Health, the Mitchell Cancer Institute (MCI) is the only academic cancer research and treatment facility on the upper Gulf Coast corridor. With more than 250 employees, including clinicians and basic researchers, MCI embraces its mission to vanquish cancer through transformative research, education, and health care. To learn more, visit www.usahealthsystem.com/mci.
Learn More
Interested in learning more? Contact our team using the button below.
1 Kolodziej, M. A., Kwiatkowsky, L., Parrinello, C., Thurow, T., Schaefer, E. S., Beck, J. T., Cherny, N., & Blau, S. (2022). ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization. Journal of Clinical Oncology, 40(16_suppl), 1508
2 Parrinello, C., Calkins, G., Kwiatkowsky, L., Schaefer, E. S., Beck, J. T., Ellis, A. R., Blau, S., Telivala, B. P., & Kolodziej, M. A. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting. Journal of Clinical Oncology, 40(16_suppl), 1528. DOI: 10.1200/JCO.2022.40.16_suppl.1528
3 Cherny, N. I., Parrinello, C. M., Kwiatkowsky, L., Hunnicutt, J., Beck, T., Schaefer, E., Thurow, T., & Kolodziej, M. (2022). Feasibility of Large-Scale Implementation of an Electronic Patient- Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center. JCO Oncology Practice, 18(12), e1918-e1926. DOI: 10.1200/OP.22.00180
4 Essell J, Ascha M, Schaefer E, Calkins G, Kwiatkowsky L, Kolodziej M, Derman B. (December 6, 2025). Remote therapeutic monitoring reduces hospitalization due to infection in patients being treated for hematological malignancy. Presented as an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting.
5 Derman, B. A., Essell, J. H., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting
6 Sharma, S., Doshi, G., Shumway, N., Schaefer, E., Dave, N., Marcus, A., Dyson, B., Derman, B., Essell, J., Ascha, M., Calkins, G., Neiman, J., Kwiatkowsky, L., & Kolodziej, M. (2025). Application of the remote therapeutic monitoring (RTM) platform to optimize adherence and manage toxicity of oral anti-cancer medications (OAM). JCO Oncology Practice, 21(suppl 10), abstract 594. DOI: 10.1200/OP.2025.21.10_suppl.594